286 related articles for article (PubMed ID: 12211221)
1. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.
White CM
J Clin Pharmacol; 2002 Sep; 42(9):963-70. PubMed ID: 12211221
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor].
Bousquet P; Gayet JL
Therapie; 2003; 58(2):113-21. PubMed ID: 12942850
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
McKenney JM
Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Cheng-Lai A
Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
McTaggart F; Buckett L; Davidson R; Holdgate G; McCormick A; Schneck D; Smith G; Warwick M
Am J Cardiol; 2001 Mar; 87(5A):28B-32B. PubMed ID: 11256847
[TBL] [Abstract][Full Text] [Related]
11. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin for the treatment of patients with hypercholesterolemia.
Chong PH; Yim BT
Ann Pharmacother; 2002 Jan; 36(1):93-101. PubMed ID: 11816268
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.
Crouse JR
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):287-304. PubMed ID: 18363544
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
Simonson SG; Martin PD; Mitchell P; Schneck DW; Lasseter KC; Warwick MJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):669-75. PubMed ID: 12610743
[TBL] [Abstract][Full Text] [Related]
19. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]